These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 10764164

  • 1. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
    Tarella C, Caracciolo D, Corradini P, Zallio F, Ladetto M, Cuttica A, Rossi G, Novero D, Gavarotti P, Pileri A.
    Leukemia; 2000 Apr; 14(4):740-7. PubMed ID: 10764164
    [Abstract] [Full Text] [Related]

  • 2. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
    Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM, Gruppo Italiano Terapie Innovative nei Linfomi.
    Leukemia; 2007 Aug; 21(8):1802-11. PubMed ID: 17554382
    [Abstract] [Full Text] [Related]

  • 3. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
    Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A.
    Cancer; 2003 Jun 01; 97(11):2748-59. PubMed ID: 12767087
    [Abstract] [Full Text] [Related]

  • 4. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
    Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ.
    Biol Blood Marrow Transplant; 2000 Jun 01; 6(5A):555-62. PubMed ID: 11071261
    [Abstract] [Full Text] [Related]

  • 5. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P, Cornillet P, Deconinck E, Tourani JM, Gardembas M, Delain M, Abgrall JF, Kootz C, Milpied N.
    Bone Marrow Transplant; 2000 Nov 01; 26(9):971-7. PubMed ID: 11100276
    [Abstract] [Full Text] [Related]

  • 6. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
    Seyfarth B, Kuse R, Sonnen R, Glass B, Schmitz N, Dreger P.
    Ann Hematol; 2001 Jul 01; 80(7):398-405. PubMed ID: 11529465
    [Abstract] [Full Text] [Related]

  • 7. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
    Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B.
    Blood; 1995 Oct 15; 86(8):3257-62. PubMed ID: 7579423
    [Abstract] [Full Text] [Related]

  • 8. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb 15; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.
    Lancet Oncol; 2017 Aug 15; 18(8):1076-1088. PubMed ID: 28668386
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
    Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H.
    Eur J Haematol; 2000 Jul 15; 65(1):17-22. PubMed ID: 10914935
    [Abstract] [Full Text] [Related]

  • 11. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial.
    Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C.
    Leukemia; 2006 Oct 15; 20(10):1840-7. PubMed ID: 16932351
    [Abstract] [Full Text] [Related]

  • 12. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L.
    J Clin Oncol; 1997 Feb 15; 15(2):491-8. PubMed ID: 9053470
    [Abstract] [Full Text] [Related]

  • 13. Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
    Wang B, Ren C, Zhang W, Ma X, Xia B, Sheng Z.
    Hematol Oncol; 2013 Mar 15; 31(1):29-33. PubMed ID: 22488650
    [Abstract] [Full Text] [Related]

  • 14. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F.
    J Clin Oncol; 1996 Feb 15; 14(2):534-42. PubMed ID: 8636768
    [Abstract] [Full Text] [Related]

  • 15. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
    Biol Blood Marrow Transplant; 1997 Oct 15; 3(4):210-6. PubMed ID: 9360783
    [Abstract] [Full Text] [Related]

  • 16. Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.
    Ballestrero A, Ferrando F, Miglino M, Clavio M, Gonella R, Garuti A, Grasso R, Ghio R, Balleari E, Gobbi M, Patrone F.
    Eur J Haematol; 2002 Feb 15; 68(2):101-6. PubMed ID: 12038448
    [Abstract] [Full Text] [Related]

  • 17. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A.
    J Clin Oncol; 2008 Jul 01; 26(19):3166-75. PubMed ID: 18490650
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD, Ogden JL, Jain VK.
    Clin Lymphoma; 2002 Mar 01; 2(4):229-37. PubMed ID: 11970762
    [Abstract] [Full Text] [Related]

  • 19. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.
    Tarella C, Zallio F, Caracciolo D, Cuttica A, Corradini P, Gavarotti P, Ladetto M, Podio V, Sargiotto A, Rossi G, Gianni AM, Pileri A.
    Leukemia; 2001 Feb 01; 15(2):256-63. PubMed ID: 11236941
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb 01; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.